Plavix Generic Blocked By Court, But Damage Lingers For Bristol And Sanofi

The impact of the launch of a generic version of Plavix - the second best selling drug in the world - will continue to weigh on Sanofi-Aventis and Bristol-Myers Squibb at least through the remainder of the year and possibly beyond despite a ruling in their favor barring Apotex' sale of generic clopidogrel

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet